Bumetanide

Introduction Overview

Generic Name

bumetanide

Brand Name

Bumex

Dosage Form

tablet

Drug Class

loop diuretics

Pharmacokinetics

Absorption

Bumetanide is rapidly absorbed after oral administration, with diuresis onset occurring within 30 to 60 minutes and peak effects reached between 1 and 2 hours. The drug exhibits nearly equal diuretic response when administered orally or parenterally, facilitating flexibility in routes of administration in clinical settings. Its rapid onset and relatively short duration of action require careful dosing intervals to maintain effective diuresis.

Distribution

Bumetanide is extensively bound to plasma proteins, with protein-binding ranging between 94% and 96%, which affects its distribution volume and pharmacodynamics. The volume of distribution has been reported to be approximately 0.26 to 0.39 L/kg in neonates, with higher protein binding observed in cord serum (about 97%), indicating a potential displacement risk of bilirubin in neonates. These pharmacokinetic properties influence its tissue penetration and clinical effects.

Metabolism

Bumetanide undergoes hepatic metabolism primarily via oxidation of the N-butyl side chain. Metabolic pathways contribute to the formation of biliary metabolites, though biliary excretion constitutes approximately only 2% of the administered dose. Concurrent administration of inhibitors of renal tubular secretion such as probenecid diminishes bumetanide's natriuretic effect, suggesting involvement of active tubular secretion in its elimination.

Elimination

Bumetanide is eliminated rapidly, with an elimination half-life of approximately 1 to 1.5 hours in adults, though this may be prolonged up to 6 hours in neonates due to immature renal and hepatic function. The majority of the drug is excreted renally, with 81% of administered radioactivity recovered in urine, approximately 45% as unchanged drug. Clearance is decreased in the elderly and in patients with renal impairment, necessitating dosage adjustments to prevent toxicity.

Dosage Forms

Adults

Bumex is available as oral tablets in strengths of 0.5 mg (light green), 1 mg (yellow), and 2 mg (peach) for adult use. The usual total daily dosage ranges from 0.5 mg to 2 mg, administered as a single dose. If response is insufficient, doses may be repeated at 4 to 5-hour intervals, not exceeding 10 mg per day. Alternative dosing regimens include intermittent schedules (e.g., alternate day dosing) for sustained edema control. In hepatic failure, dosing should be minimized and carefully titrated.

Adolescents

Safety and effectiveness in pediatric patients under 18 years old have not been established. Pharmacokinetic studies in neonates indicate markedly delayed elimination and increased protein binding. Therefore, use in pediatric populations requires caution, with dosing individualized and monitored in specialized settings.

Special Populations

In neonates and infants, bumetanide elimination is significantly slower due to immature renal and hepatobiliary function, with half-life up to 6 hours or longer. In elderly patients, clearance is reduced and plasma levels may be higher, warranting cautious dosing starting at lower ranges. In patients with hepatic failure, dosing should be minimized to prevent excessive volume and electrolyte depletion. Renal impairment can prolong drug half-life and increase risk of toxicity, requiring close monitoring and dose adjustment.

Mechanism Of Action

Bumetanide is a potent loop diuretic which exerts its primary action in the thick ascending limb of the loop of Henle in the nephron. It inhibits the Na^+/K^+/2Cl^- symporter, thereby blocking sodium and chloride reabsorption. This inhibition causes increased excretion of sodium, chloride, and water, resulting in diuresis and reduction of edema. The drug also interferes with free water clearance by inhibiting tubular reabsorption, demonstrating chloruretic predominance over natriuretic effect.

Additionally, bumetanide may exert minor effects in the proximal tubule, evidenced by increased phosphate excretion (phosphaturia) during diuresis and interaction with probenecid which reduces its natriuretic effect by inhibiting tubular secretion. Bumetanide does not significantly affect the distal tubule.

The clinical relevance of bumetanide’s mechanism is reflected in its rapid onset and short duration of action relative to other loop diuretics such as furosemide, with a diuretic potency approximately 40 times greater. This potency allows for lower dosages to achieve equivalent diuretic effects. The biochemical inhibition of the Na^+/K^+/2Cl^- symporter impairs the kidney’s ability to concentrate urine, promoting fluid loss and electrolyte excretion. These mechanisms underpin its therapeutic use in treating edema associated with cardiac, hepatic, and renal conditions.

Pharmacological Actions

Potent loop diuretic effect via inhibition of sodium and chloride reabsorption in the thick ascending limb of the loop of Henle
Increases excretion of sodium, chloride, potassium, and water leading to diuresis
Blocks free-water clearance and promotes chloruretic activity
Causes increased urinary phosphate excretion via proximal tubular effects
Reduces plasma volume thereby decreasing edema and fluid overload
Increases renal excretion of calcium and magnesium, potentially leading to electrolyte imbalances
Inhibits sodium-potassium-chloride symporter leading to decreased renal concentrating ability
Exhibits rapid onset and short duration of diuretic action
Has little effect on distal tubule sodium reabsorption
Reduces uric acid excretion leading to increased serum uric acid levels
May displace bilirubin in neonates due to high protein binding

Therapeutic Clinical Uses

Treatment of edema associated with congestive heart failure
Management of edema due to hepatic disease such as cirrhosis and ascites
Edema management in renal diseases including nephrotic syndrome
Alternative diuretic in patients allergic to furosemide due to rare cross-sensitivity
Use as parenteral diuretic when oral administration is impractical or absorption is impaired
Treatment of volume overload states requiring rapid diuresis
Adjunct therapy in hypertension management when indicated
Management of fluid retention in geriatric patients with renal impairment
Occasionally used in nephrotic syndrome to aid diuresis with careful electrolyte monitoring
Used in acute care settings requiring potent diuresis

Side Or Adverse Effects

Muscle cramps, reported in approximately 1.1% of patients
Dizziness and hypotension due to volume depletion, 0.8 to 1.1% incidence
Headache and nausea seen in about 0.6% of cases
Encephalopathy reported in patients with pre-existing liver disease
Ototoxicity observed mainly in animal models; rarely in humans, especially with high-dose IV therapy
Serious skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis
Impaired hearing and tinnitus reported in less than 1% of patients
Electrolyte disturbances: hypokalemia, hyponatremia, hypochloremia, hypomagnesemia
Hyperuricemia occurs in about 18% of patients, potentially leading to gout
Azotemia and increased serum creatinine indicating renal function changes
Thrombocytopenia rare but reported in postmarketing experience
Dehydration and volume depletion symptoms like weakness and fatigue
Gastrointestinal complaints including abdominal pain, vomiting, and diarrhea
Laboratory abnormalities including hyperglycemia and changes in liver enzymes
Potential for allergic reactions especially in sulfonamide-sensitive individuals

Precautions

Monitor serum potassium regularly to detect hypokalemia; supplement potassium or add potassium-sparing diuretics if needed
Periodic assessment of other electrolytes advisable in patients on prolonged or high-dose therapy
Careful monitoring of fluid status to prevent dehydration and circulatory collapse
Avoid use in patients with anuria or severe electrolyte depletion until corrected
Use cautiously in patients with hepatic cirrhosis and ascites to avoid precipitating hepatic encephalopathy
Serum glucose should be periodically measured in diabetic or suspected diabetic patients due to potential hyperglycemia
Regular monitoring recommended for blood dyscrasias, hepatic impairment, or idiosyncratic reactions
Avoid concomitant use with nephrotoxic drugs to prevent renal injury
Caution in use with drugs having ototoxic potential to avoid additive toxicity
Avoid use in critically ill or jaundiced neonates due to risk of bilirubin displacement
Dose starting should be low in elderly patients with reduced renal function
Monitor renal function carefully due to risk of increased BUN and creatinine
Avoid concomitant use with probenecid as it reduces bumetanide efficacy
Cautious use in patients receiving digitalis, due to risk of arrhythmias from hypokalemia

Warnings

Excessive dosing can cause profound diuresis leading to water and electrolyte depletion, dehydration, and circulatory collapse
Risk of hypokalemia which can predispose to ventricular arrhythmias, especially in patients on digitalis
Potential ototoxicity, especially with high dose intravenous use or in presence of renal impairment
Allergic cross-reactivity with sulfonamides may occur, leading to hypersensitivity reactions
Risk of thrombocytopenia; patients should be observed for hematologic abnormalities
Volume depletion can precipitate thrombosis and embolism, particularly in elderly patients
Avoid use in hepatic coma or severe electrolyte depleted states until correction
Potential increased risk of hepatic encephalopathy due to electrolyte shifts in patients with cirrhosis
Interactions with other drugs may potentiate hypotension or nephrotoxicity
Drug should not be used in anuria or significant renal failure without careful supervision
Risk of metabolic alkalosis with prolonged use

Contraindications

Anuria or absence of urine formation
Known hypersensitivity to bumetanide or other sulfonamide-derived drugs
Severe electrolyte depletion (hypokalemia, hyponatremia) not corrected prior to therapy
Hepatic coma or pre-comatose states associated with severe electrolyte imbalance
Patients with progressive renal disease experiencing marked azotemia or oliguria during therapy
History of allergic reaction to bumetanide or sulfonamides
Use not recommended in pediatric patients below 18 years due to lack of established safety
Avoid concurrent use with probenecid due to antagonism of diuretic effect

Drug Interactions

Probenecid decreases renal tubular secretion of bumetanide, reducing its natriuretic effect; concurrent use contraindicated
Indomethacin blunts the diuretic response and inhibits bumetanide-induced plasma renin activity; concurrent therapy not recommended
Aminoglycoside antibiotics may have additive ototoxic effects, especially with impaired renal function; avoid together when possible
Lithium renal clearance is reduced by diuretics including bumetanide, increasing risk of lithium toxicity
Potentiation of antihypertensive drugs may occur, requiring dosage adjustments
No significant interaction observed with digoxin levels
Warfarin metabolism and prothrombin activity not significantly affected
Concomitant use with nephrotoxic drugs should be avoided due to potential for renal injury
Electrolyte disturbances may be exacerbated when combined with other diuretics or corticosteroids
NSAIDs may attenuate diuretic and antihypertensive effects
Concurrent use with potassium-sparing diuretics may help minimize hypokalemia but needs monitoring

Preparations Of The Drug

Bumex tablets for oral administration available in elliptical, flat-faced, bevel-edged forms
Available dosages: 0.5 mg tablets (light green, imprint 'BUMEX 0.5')
1 mg tablets (yellow, imprint 'BUMEX 1')
2 mg tablets (peach/orange, imprint 'BUMEX 2')
Supplied in bottles of 100 or 500 tablets
Tablets contain inactive ingredients including anhydrous lactose, magnesium stearate, microcrystalline cellulose, corn starch, talc, and color additives depending on strength
Stored at controlled room temperature (20° to 25°C), allowed excursions between 15° to 30°C
Also available as parenteral injection (intravenous and intramuscular) for patients unable to take oral medications